Stem Cell Transplant or Cellular Therapy - Allogeneic

- AML/MDS/ALL
  - MDS Only
  - AML Only
  - AML/ MDS Only
  - AML/ MDS/ALL
  - High Risk
  - Multiple Myeloma
  - Severe Aplastic Anemia

- Multiple Diseases

**IRB# 10146**
Compares reduced intensity allogeneic stem cell transplant to hypomethylating therapy or best supportive care in patients aged 50-75 with intermediate - 2 and high risk myelodysplastic syndrome.

**IRB# 17622**
Tests the drug Gilteritinib with a placebo for AML with a FLT3/ITD mutation after allogeneic transplant.

**IRB# 16995**
Tests the drug Pro 140 compared to placebo to prevent Graft vs. Host Disease in AML and MDS patients undergoing allogeneic stem cell transplants.

**IRB# 16189**
Phase 1/phase 2 study of ProTmune ex vivo mobilized peripheral blood cells.

**IRB# 11907**
BEAM Conditioning for Allogeneic Hematopoietic Transplant for Sibling or Unrelated donors.

**IRB# 16943**
BMT CTN phase II study of ATG-based conditioning regimens for haploidentical and cord blood transplants.

**IRB# 16982**
Donor T-Cell infusion for adults with recurrent minimal residual disease post HSCT.

**IRB# 18301**
Transplantation of Ex Vivo Expanded, UCB-derived, Stem & Progenitor Cells vs. Unmanipulated UCB for HM Patients.

**IRB# 9375**
Phase 1-2 BPX-501 T Cells after Partially Mismatched, Related Donor T Cell-Depleted Stem Cell Transplant.

Key:
- Open for Enrollment
- In Development
- Enrollment on Hold

http://www.ohsu.edu/research/rda/so/knight.php

4/9/2018